Agios Pharmaceuticals Inc

Research Agios Pharmaceuticals Inc (AGIO) on Bullrun: market cap USD 2.26B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerAGIO
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 2.26B
• Financial periodFY2025
• RevenueUSD 54.03M
• Revenue growth48.0%
• Net income-USD 413.00M
• Free cash flow-USD 377.29M
• Gross margin88.3%

Valuation Snapshot

latest market cap is USD 2.26B.

About Agios Pharmaceuticals Inc

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients;

Frequently asked questions

What is Agios Pharmaceuticals Inc's market cap?

Agios Pharmaceuticals Inc's market capitalization is USD 2.26B.

What does Agios Pharmaceuticals Inc do?

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States.